Tissue Repair Ltd (TRP.AX)
AUD 0.27
(0.0%)
AUD 0.27
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -5.77 Million AUD | -26.73% |
| 2023 | -5.14 Million AUD | 16.07% |
| 2022 | -7 Million AUD | -968.61% |
| 2021 | -189.44 Thousand AUD | -42.56% |
| 2020 | -52.19 Thousand AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | -1.17 Million AUD | 0.0% |
| 2024 Q2 | -2.53 Million AUD | -78.16% |
| 2024 Q1 | -1.26 Million AUD | 36.27% |
| 2024 FY | - AUD | -13.54% |
| 2024 Q3 | -1.17 Million AUD | 48.07% |
| 2023 Q1 | -1.69 Million AUD | 29.55% |
| 2023 FY | - AUD | 16.07% |
| 2023 Q4 | -2.35 Million AUD | -239.74% |
| 2023 Q3 | -693.11 Thousand AUD | 79.51% |
| 2023 Q2 | -3.38 Million AUD | -100.0% |
| 2022 FY | - AUD | -968.61% |
| 2022 Q4 | -2.4 Million AUD | -115.43% |
| 2022 Q3 | -1.11 Million AUD | 38.87% |
| 2022 Q2 | -1.82 Million AUD | -100.0% |
| 2022 Q1 | -911.48 Thousand AUD | -310.2% |
| 2021 Q1 | 8854.00 AUD | 0.0% |
| 2021 FY | - AUD | -42.56% |
| 2021 Q4 | -222.2 Thousand AUD | 0.0% |
| 2021 Q3 | -222.2 Thousand AUD | -2609.94% |
| 2021 Q2 | 8853.00 AUD | -0.01% |
| 2020 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 155.66% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -296.453% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 84.153% |
| Biome Australia Limited | -1.57 Million AUD | -265.911% |
| Patrys Limited | -3.49 Million AUD | -65.371% |
| Orthocell Limited | -11.68 Million AUD | 50.561% |
| Imugene Limited | -147.97 Million AUD | 96.097% |
| Noxopharm Limited | -5.94 Million AUD | 2.868% |
| PYC Therapeutics Limited | -38.11 Million AUD | 84.85% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | 48.893% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 19.632% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | 26.781% |
| Cynata Therapeutics Limited | -9.95 Million AUD | 41.961% |
| CSL Limited | 4.73 Billion AUD | 100.122% |
| Arovella Therapeutics Limited | -8.83 Million AUD | 34.621% |
| Bio-Gene Technology Limited | -2.97 Million AUD | -94.118% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 111.135% |
| Starpharma Holdings Limited | -12.57 Million AUD | 54.083% |
| Nanollose Limited | -1.14 Million AUD | -403.092% |
| Memphasys Limited | -3.3 Million AUD | -74.591% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -701.592% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -221.497% |
| Amplia Therapeutics Limited | -4.55 Million AUD | -26.656% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 58.511% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | -104.924% |
| Race Oncology Limited | -14.2 Million AUD | 59.341% |
| Nyrada Inc. | -4.59 Million AUD | -25.647% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 125.146% |
| Dimerix Limited | -24.95 Million AUD | 76.862% |
| PharmAust Limited | -9.45 Million AUD | 38.9% |
| Immutep Limited | -42.87 Million AUD | 86.531% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 87.065% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 70.493% |
| BTC Health Limited | 1.05 Million AUD | 647.244% |
| Acrux Limited | -7.93 Million AUD | 27.185% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 102.898% |
| Biotron Limited | -5.04 Million AUD | -14.582% |
| AdAlta Limited | -5.3 Million AUD | -8.907% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 87.273% |
| Hexima Limited | -995.54 Thousand AUD | -480.085% |
| AnteoTech Limited | -11.57 Million AUD | 50.091% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 91.052% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 72.956% |
| Avecho Biotechnology Limited | -3.24 Million AUD | -78.103% |
| Actinogen Medical Limited | -12.92 Million AUD | 55.306% |
| Immuron Limited | -6.19 Million AUD | 6.74% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -204.333% |